Merus (NASDAQ:MRUS) Price Target Raised to $110.00

Merus (NASDAQ:MRUS) had its price objective upped by BMO Capital Markets from $96.00 to $110.00 in a research note released on Friday,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock.

A number of other research firms also recently weighed in on MRUS. Piper Sandler assumed coverage on shares of Merus in a research note on Thursday, February 13th. They issued an “overweight” rating and a $84.00 price target on the stock. Wells Fargo & Company lowered their target price on shares of Merus from $91.00 to $89.00 and set an “overweight” rating on the stock in a research report on Thursday, May 8th. Bank of America lowered their target price on shares of Merus from $73.00 to $70.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. William Blair reissued an “outperform” rating on shares of Merus in a research report on Monday, April 28th. Finally, Guggenheim reissued a “buy” rating and set a $109.00 target price on shares of Merus in a research report on Friday, March 28th. Fourteen investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $86.00.

Merus Trading Up 32.5%

NASDAQ MRUS opened at $55.14 on Friday. Merus has a 1-year low of $33.19 and a 1-year high of $61.28. The company has a market capitalization of $3.82 billion, a PE ratio of -13.96 and a beta of 0.94. The firm’s fifty day simple moving average is $42.72 and its 200-day simple moving average is $43.41.

Merus (NASDAQ:MRUS) last posted its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.23). Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The company had revenue of $26.49 million during the quarter, compared to analyst estimates of $7.82 million. As a group, analysts predict that Merus will post -3.85 EPS for the current year.

Institutional Investors Weigh In On Merus

Hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC boosted its holdings in Merus by 2,153.6% during the first quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 603 shares during the period. State of Wyoming bought a new stake in Merus during the fourth quarter valued at about $48,000. Wells Fargo & Company MN boosted its holdings in Merus by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 300 shares during the period. GF Fund Management CO. LTD. bought a new stake in Merus during the fourth quarter valued at about $60,000. Finally, Avior Wealth Management LLC bought a new stake in Merus during the fourth quarter valued at about $76,000. 96.14% of the stock is currently owned by institutional investors.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.